Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

unprecedented number of orphan receptors, and our addiction and high-risk bleeding programs advanced toward the clinic. Following the close of the quarter, we added over $17 million to our balance sheet, positioning Omeros to execute on a series of value-driving milestones during the remainder of 2013 and well into 2014."

Third Quarter and Recent Highlights

  • Reported U.S. and European regulators had accepted Omeros' OMS302 marketing applications for review. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery® product designed to maintain intraoperative mydriasis, prevent miosis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. Omeros is preparing for a planned commercial launch of OMS302 in the second half of 2014.
  • Announced that Omeros entered into a settlement agreement with Carolina Casualty Insurance Company, or, CCIC, dated October 2, 2013, related to CCIC's defense of, and coverage obligations owed to, Omeros and its chief executive officer and chairman, Dr. Demopulos, in previously settled litigation with Omeros' former chief financial officer. The settlement included a release of each party's respective claims in the insurance coverage lawsuit and payment by CCIC of $12.5 million to Omeros, which was received on October 24, 2013.
  • Reported positive clinical data from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia.  Omeros subsequently started a Phase 2 trial evaluating the drug in patients with schizophrenia and plans to start a Phase 2 trial in Huntington's disease in early 2014. OMS824 has received orphan drug designation from the
    '/>"/>

  • SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros to Present at the 12th Annual Needham Healthcare Conference
    3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
    10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
    11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal Products ... selected by Buffalo BioBlower Technologies LLC ("B3") as the ... Phase 2 award from the Army Corps of Engineers.  ... that kills all biological contaminants and destroys VOCs and ...
    (Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ...
    (Date:1/15/2014)... ­ RedBrick Health , a fast-growing leader in ... that EmblemHealth , the New York ... providing the RedBrick Compass health assessment, combined with the ... its members. EmblemHealth is among the first health plans ...
    (Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
    Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
    ... Sept. 6 Globally, approximately 418 million,people are ... and costs of hepatitis in the 21st century ... Strategies, a,new report by Kalorama Information. Paradoxically, ... the necessary steps to contain hepatitis. Yet the ...
    ... 6 Philip Young, Chief Executive Officer,of Osteologix, ... be featured in an exclusive interview with ... September 6 at 11 a.m. EDT. The interview ... p.m. EDT on September 6. The interview ...
    ... (Nasdaq: NPSP ) announced today that it has ... its outstanding 3.0% Convertible,Notes due 2008. The tender offer ... unless extended. The tender offer, which is described,fully in ... transmittal, is not,subject to the receipt of any minimum ...
    Cached Biology Technology:Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health 2WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of Osteologix 2NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 2NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 3NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 4
    (Date:4/17/2014)... Professor Luca Razzari of the nergie Matriaux Tlcommunications ... from the John R. Evans Leaders Fund of ... acquisition of state-of-the-art biotech and nanophotonics equipment. To ... the Ministre de l,Enseignement suprieur, de la Recherche, ... These new laboratories will help us develop new ...
    (Date:4/17/2014)... in German . ... they also provide us with a continuous stream of information ... or sit still in a car the world glides ... retinas. Seemingly without effort, our brain calculates self-motion from this ... and a steady gaze during our own movements. Together with ...
    (Date:4/17/2014)... about eight years ago, Katia Silvera , a postdoctoral ... were on a field trip in a mountainous area in ... never seen before. , Unable to identify it, they contacted ... turned out to be an unnamed species. So Carnevali recently ... "Lophiaris" is the genus name, comprising about 40 species in ...
    Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
    ... tool, Johns Hopkins scientists report that they have refined a ... sending them to exact locations at precise times. ... ever in manipulating single molecules, allowing them to see how ... to determine whether cells will grow, die, move or divide. ...
    ... Spanish . U.S. Department of Agriculture ... for methyl bromide are studying an alternative soil treatment that ... USDA,s Agricultural Research Service (ARS) are examining whether a cropping ... used to replace the popular fumigant. They also are studying ...
    ... cells and then clicking off the light makes the cells ... for chemotherapy drugs, as well as a non-invasive way to ... a report in ACS,s The Journal of Physical Chemistry ... colleagues note using this technique before to force cancer cells ...
    Cached Biology News:Hopkins researchers use light to move molecules 2Alternatives eyed for methyl bromide 2
    Request Info...
    Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
    Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
    ... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
    Biology Products: